Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Retained Earnings (2016 - 2025)

Voyager Therapeutics' Retained Earnings history spans 11 years, with the latest figure at -$445.9 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 36.7% year-over-year to -$445.9 million; the TTM value through Dec 2025 reached -$445.9 million, down 36.7%, while the annual FY2025 figure was -$445.9 million, 36.7% down from the prior year.
  • Retained Earnings for Q4 2025 was -$445.9 million at Voyager Therapeutics, down from $7000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $7000.0 in Q3 2025 and bottomed at -$445.9 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$311.9 million (2021), against an average of -$255.4 million.
  • The largest annual shift saw Retained Earnings plummeted 288884.38% in 2022 before it skyrocketed 100.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$347.1 million in 2021, then dropped by 13.37% to -$393.5 million in 2022, then soared by 33.63% to -$261.2 million in 2023, then decreased by 24.89% to -$326.2 million in 2024, then plummeted by 36.7% to -$445.9 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Retained Earnings are -$445.9 million (Q4 2025), $7000.0 (Q3 2025), and -$390.6 million (Q2 2025).